MGB Division of Infectious Diseases

@mgb-id.bsky.social

Patient-centered, innovative care. Groundbreaking basic, translational, and clinical research.

New multi-center research by faculty Dr. Obeid, Dr. Young & colleagues highlights severe challenges in treating refractory HSV in stem cell transplant recipients. With high acyclovir resistance & drug toxicity, their findings stress the urgent need for safer, oral antivirals. #IDSky

Refractory Mucocutaneous Infections by Herpes Simplex Virus (HSV) in Hematopoietic Cell Transplant Recipients: A Real-world, Multicenter Study

A total of 55.2% HCT recipients with refractory HSV healed completely at a median of 38 days of therapy. Seventy-five percent of patients received foscarne

academic.oup.com